Aktis Oncology (AKTS): Largest Biotech IPO in Two Years and Likely to be Acquired

Aktis Oncology is developing alpha particle-emitting radiopharmaceuticals for the treatment of multiple solid tumor types. The company's lead asset, AKY-1189, targets Nectin-4 and has the potential to be a multi-cancer radiopharmaceutical. The company is expected to have a successful IPO and is a likely acquisition target.